check_circleStudy Completed
Hepatocellular cancer
Bayer Identifier:
22241
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Real World Treatment Patterns After Use of Atezolizumab and Bevacizumab Combination Therapy in Patients with Hepatocellular Cancer
Trial purpose
This study is a retrospective cohort analysis of patients diagnosed with HCC and with use of atezo+bev combination as first observed therapy between June 1, 2020,
and June 30, 2022.
and June 30, 2022.
Key Participants Requirements
Sex
AllAge
18 - N/ATrial summary
Enrollment Goal
825Trial Dates
April 2022 - June 2022Phase
N/ACould I Receive a placebo
NoProducts
Stivarga (Regorafenib, BAY73-4506)Accepts Healthy Volunteer
NoPrimary Outcome
- Percentage of patients receiving any other systemic HCC therapy after first observed (index) atezo+bev in HCC patients treated in real-world clinical practicedate_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
- Describe which therapies are used after index atezo+bev among HCC patientsIncluding, but not limited to, the proportion of patients receiving sorafenib, regorafenib, lenvatinib, cabozantinib, and any other systemic HCC therapy (including nivolumab, pembrolizumab, ramucirumab, ipilimumab) after index atezo+bevdate_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
Secondary Outcome
- Proportion of patients switching at different timepoints (i.e., at 3-, 6-, 9-, and 12-months post-index and over the entire study period)date_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
- Baseline characteristics of 3 subgroups of HCC patients:a. All patients receiving index atezo+bev; b. Patients not switching to another therapy after index atezo+bev (non-switchers); c. Patients switching to subsequent HCC therapy after index atezo+bev (switchers);date_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
- Treatment sequence for all treatments received post index atezo+bevdate_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
- time to discontinuation (TTD) for index atezo+bev and time to the first post atezo+bev systemic HCC therapy for switchersdate_rangeTime Frame:Retrospective analysis between June 1, 2020, and June 30, 2022
Trial design
Trial Type
ObservationalIntervention Type
OtherTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A